Financial Performance - The company experienced a significant decline in performance compared to the same period last year due to factors such as international trade environment and fluctuations in major customer orders [3]. - The company's operating revenue for 2024 was ¥497,010,912.73, a decrease of 35.19% compared to ¥766,824,305.02 in 2023 [22]. - The net profit attributable to shareholders for 2024 was ¥38,609,322.43, down 77.76% from ¥173,574,166.37 in 2023 [22]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥17,362,547.32, a decline of 89.66% from ¥167,843,305.36 in 2023 [22]. - The basic earnings per share for 2024 was ¥0.32, representing an 81.50% decrease from ¥1.73 in 2023 [22]. - The total assets at the end of 2024 were ¥2,263,389,145.02, a decrease of 2.04% from ¥2,310,635,609.21 at the end of 2023 [22]. - The net assets attributable to shareholders at the end of 2024 were ¥2,148,819,290.03, down 1.02% from ¥2,171,004,806.01 at the end of 2023 [22]. - The company reported a net cash flow from operating activities of ¥154,897,880.33, a slight decrease of 0.17% compared to ¥155,156,353.42 in 2023 [22]. Dividend Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 4.00 RMB per 10 shares (including tax) to all shareholders based on 120,446,669 shares [4]. - The company distributed a total cash dividend of RMB 68.8267 million, accounting for 39.65% of the net profit attributable to shareholders for the year 2023 [118]. - The proposed cash dividend for 2024 is RMB 4.00 per 10 shares, totaling RMB 48.1787 million, which represents 124.79% of the net profit for the year [121]. Market Position and Strategy - The company aims to enhance service capabilities, increase overseas investments, and optimize customer structure to mitigate related risks in the future [3]. - The company is focused on expanding its market presence and developing new products and technologies to drive future growth [4]. - The company is positioned to benefit from the ongoing growth in the global pharmaceutical market and the increasing outsourcing trend in drug development [31]. - The company plans to enhance service capabilities by upgrading laboratory hardware and software, increasing R&D investment, and improving comprehensive service capabilities from laboratory services to API production [77]. - The company will increase investment in its U.S. production base by acquiring land, expanding facilities, and updating equipment to better serve local customers and mitigate trade policy impacts [78]. - The company aims to optimize its customer structure by strengthening its business development team and expanding into the Asia-Europe market to reduce the impact of trade policies and customer fluctuations [78]. Research and Development - The company increased its R&D investment to 7.15% of operating revenue, with a year-on-year increase of 18.29% [44]. - The company is focusing on the development of fluorinated compounds and aims to enhance its market competitiveness through various R&D projects [53][54]. - The company has developed numerous process routes for small molecule compounds, addressing technical bottlenecks and ensuring implementation of R&D routes [36]. - The company provides comprehensive CDMO services, from gram-scale sample process development to kilogram and ton-scale production, enhancing R&D efficiency and reducing costs for clients [35]. Environmental Compliance - The company complies with multiple environmental protection laws and regulations, including the Clean Water Act and Clean Air Act [128]. - The company invested CNY 41.4954 million in environmental protection during the reporting period and paid CNY 5,600 in environmental protection tax [137]. - The company purchased a total of 14,925,000 kWh of green electricity, resulting in a reduction of 13,013,107.50 kg of CO2 emissions, 7,014.75 kg of SO2, and 6,417.75 kg of nitrogen oxides [137]. - The company has a wastewater treatment capacity of 700 tons per day, utilizing a multi-step treatment process to ensure compliance with discharge standards [132]. - The company received the provincial-level green factory title from the Liaoning Provincial Department of Industry and Information Technology in September 2023 [132]. Governance and Management - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments, urging investors to remain aware of investment risks [3]. - The company has established a governance structure that includes a board of directors, supervisory board, and shareholder meetings, all operating independently from controlling shareholders [88]. - The company has implemented a performance-based remuneration system for its employees [104]. - The total remuneration for directors, supervisors, and senior management in 2024 is 11.3146 million yuan [104]. - The company has a structured remuneration decision process involving the board and shareholders [104]. Risks and Challenges - The company faces risks related to changes in international trade policies, which may impact its overseas business operations [76]. - The company faces risks from fluctuations in terminal demand due to operational pressures on global pharmaceutical companies and financing challenges for small innovative drug firms, which could impact revenue significantly [77]. - The investment progress of the company has been slow due to changes in international trade policies and fluctuations in new drug terminal demand [71]. Shareholder Relations - The company held its first temporary shareholders' meeting in January 2024 with a participation rate of 59.35% [91]. - The company’s annual shareholders' meeting in April 2024 had a participation rate of 59.29% [91]. - The second temporary shareholders' meeting in September 2024 had a participation rate of 58.68% [91]. - The company has ensured that all remuneration payments were made in full according to the established standards [104]. Financial Management - The company has a total of 120,446,669 shares after the capital reserve conversion, with a 40% increase from the previous total [194]. - The company has entrusted financial management with a total of 133,457.22 million CNY, with no overdue amounts [188]. - The company has a total of 711 employees, with 451 in production, 155 in technical roles, and 14 in sales [115]. Compliance and Legal Matters - The company has not faced any penalties or rectification issues during the reporting period [174]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant debts due [175]. - The company reported no related party transactions during the reporting period [176].
金凯生科(301509) - 2024 Q4 - 年度财报